Biophan to Showcase Latest Technology and Research Results at Heart Rhythm 2004 Conference; San Francisco Conference to Focus on Latest Science and Applications of Heart Rhythm Management.

Business Editors/Health/Medical Writers

BIOWIRE2K

Heart Rhythm 2004 Conference

ROCHESTER, N.Y--(BUSINESS WIRE)--May 11, 2004

Biophan Technologies, Inc. (OTCBB: BIPH) an innovator, developer and marketer of MRI-related and other advanced biomedical technology, announced today that it will exhibit at the NASPE - Heart Rhythm Society's Heart Rhythm 2004 Conference. The conference focuses on showcasing the latest science, techniques, and procedures in the cardiac and electrophysiology industries, and will take place May 19-22, 2004 at The Moscone Center in San Francisco, CA.

According to the Society, over 6,000 healthcare professionals have registered to attend the conference to learn more about the newest advances in heart rhythm management. At the Conference, the Company's exhibit will include information regarding a recent study at the University of Rochester confirming the danger to pacemaker patients caused by both excessive tissue heating and interference with proper pacemaker functionality.

To date, several million people who have pacemakers have been denied the benefit of magnetic resonance imaging (MRI) diagnostics due to the risk of injury or death. Medtronic (NYSE:MDT), one of the leading manufacturers of pacemakers, recently announced that more than half of pacemaker recipients are denied MRI due to safety problems, and stated that pacemakers offering MRI Safety "will be the new gold standard."

At last year's conference Biophan provided research results showing the effectiveness of an RF filter technology, based on a patented solution developed at Johns Hopkins University, and licensed exclusively to Biophan for implantable devices. The RF filter was prototyped and tested in an MRI machine and shown to reduce the negative effects of device heating to within the FDA guidelines of less than 2 degrees Centigrade. The recently conducted study results, to be released at the Conference, shows an off the shelf pacemaker experienced lead heating significantly in excess of FDA guidelines, when tested in heart tissue in an MRI machine.

Michael Weiner, Biophan's CEO, stated, "Our strategy has always been to improve the utility of MRI diagnostics by making all biomedical devices safe and image compatible for use with MRI. We feel this conference is a perfect venue to showcase our most recent discovery that can save lives and be utilized by the multi-billion pacemaker and defibrillator market. By providing both conclusive proof of the danger of pacemaker device heating and induced voltages that can cause rapid heart beats, and a viable solution that can be affordably deployed into future devices, there is no longer any need for pacemaker patients to be denied MRI. With the evidence of the problem now demonstrated, and a solution at hand, it is only a matter of time before pacemakers will be made safe and compatible with this ever growing and important MRI diagnostic capability," Weiner explained.

"Additionally, with our nanomagnetic particle thin film coating, we can also minimize the effects of image artifacts, so that pacemakers and pacemaker leads, once made safe, can also be imaged under MRI. Our technology also allows the pacemaker lead, and the stylet used to introduce it, to be visible under MRI to aid in installations using MRI vs. X-Ray and fluoroscopy. This can benefit not only the pacemaker patient, but the physician implanting the pacemaker. Today cardiologists and electrophysiologists who implant pacemakers have to wear heavy lead aprons to avoid exposure to ionizing radiation. Many are reported to suffer back problems as a result. With an MRI safe pacemaker that is also image compatible, future pacemakers (and defibrillators) can be implanted without the need for the use of the lead aprons. The benefits accrue to the patient, the physician, and the device manufacturers."

About Biophan Technologies

Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices--such as cardiac pacemakers, surgical and diagnostic tools--safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have nine issued U.S. patents and over fifty patents pending, in areas including nanomagnetic particle coatings, radio frequency filters, polymer composites, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com.

About the Heart Rhythm 2004 Conference

NASPE - Heart Rhythm Society, incorporated in 1979, has a membership of approximately 3,500 physicians and associated professionals from around the globe. NASPE - Heart Rhythm Society is the dominant professional group representing the allied specialties of cardiac pacing and electrophysiology in North America. For more information on the Heart Rhythm 2004 Conference, please visit http://www.naspe.org/SS04.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of the Company's MRI technologies; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs; the acceptance by the market of the Company's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.